Twist Bioscience Corp experienced a significant drop in its stock price, raising concerns among investors.
Twist Bioscience Corp (NASDAQ:TWST) saw its stock price fall by 18.55% in yesterday's trading session, closing at CA$166.97. This sharp decline has left investors questioning the company's future prospects.
Advertisement
Twist Bioscience Corp
TWST.US
TWST.US
Twist Bioscience Corp
WealthAwesomeMarket cap
$9.89B
52W high
$219.71
52W low
$23.30
1W change
+0.65%
Beta
2.19
Analyst Price Targets
Based on 13 analysts covering TWST · as of Oct 14, 2026
Wall Street analysts forecast TWST stock price to rise 9.7% over the next 12 months.
Consensus
Buy4.08 / 5.00
Avg. Target
C$163.67
+9.7% Upside
Previously C$157.42 on Oct 13, 2026
Current Price
C$149.13
Last close
Analyst Breakdown (13 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TWST's historical volatility
30-Day Vol
100.7%
Annualized
90-Day Vol
91.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$178.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$158.28 | C$111.81 – C$224.05 |
| 60 trading days | C$167.98 | C$102.76 – C$274.62 |
| 90 trading days | C$178.29 | C$97.65 – C$325.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent drop in Twist Bioscience's stock price highlights the volatility and risks associated with biotech investments, especially in the context of evolving technologies and market expectations.
18.55% decline in stock price
Twist Bioscience's market capitalization now stands at approximately $11.07 billion following the significant drop.
Bull case
Despite the recent downturn, some analysts are optimistic about Twist Bioscience's potential in AI-driven drug discovery. They believe this focus could lead to substantial long-term growth as the company navigates this innovative field.
Bear case
On the flip side, concerns about overvaluation and execution risks in the competitive biotech landscape have led some analysts to issue bearish ratings on Twist Bioscience. They suggest that the recent price drop may be more of a correction than just a temporary setback.
Advertisement
Market Reaction and Analyst Sentiment
The significant drop in Twist Bioscience's stock price has sparked a mixed reaction among analysts. While some maintain a bullish outlook on the company's potential in AI-driven drug discovery, others express concerns about recent overvaluation and execution risks. The disparity in analyst sentiment reflects the broader uncertainty in the biotech sector, particularly as companies navigate the complexities of personalized medicine.
The Competitive Landscape
Twist Bioscience operates in a highly competitive environment, facing increasing pressure from both established players and emerging biotech firms. The recent downturn in stock price may signal investor caution as the company struggles to demonstrate the commercial viability of its AI-driven solutions. As the market for personalized mRNA cancer vaccines and other innovative therapies evolves, Twist Bioscience's ability to adapt and differentiate itself will be crucial for regaining investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
